All Updates

All Updates

icon
Filter
Funding
Q Bio secures USD 27 million in funding to launch Mark I scanner
Digital Twin
Jul 18, 2024
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Product updates
Partnerships
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Digital Twin

Digital Twin

Jul 18, 2024

Q Bio secures USD 27 million in funding to launch Mark I scanner

Funding

  • Q Bio, a predictive assessment platform provider, raised USD 27 million in strategic funding led by TELUS Global Ventures, with participation from existing investors Khosla Ventures, Andreessen Horowitz, Founders Fund, and Kaiser Foundation Hospitals. The funding will propel Q Bio's Mark I full-body scanner toward market launch.

  • The funding will accelerate manufacturing plans for the Mark I scanner as Q Bio continues its regulatory approval process in the US. The Mark I offers full-body scans with quantifiable data across 3,000 anatomical measurements in a 10-minute scan. AI then generates a digital twin of the patient, assessing current concerns and predicting potential diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.